Abstract
The Charlson Comorbidity Index plus three comorbidity scales were evaluated for survival after radiochemotherapy of limited stage SCLC. For the Charlson Comorbidity Index, 2-4 points were compared to 5-8 points. For the Age-Comorbidity Score, 2-6 points were compared to 7-10 points. For the Medical Research Council (MRC) Breathlessness Scale, grades 0-2 were compared to grades 3-5. For the Simplified Comorbidity Score, 0-5 points were compared to 6-11 and 12-17 points. Charlson Comorbidity Index (p=0.022) and MRC Breathlessness Scale (p<0.001) showed significant associations with survival, the Age-Comorbidity Score a trend (p=0.06). For the Simplified Comorbidity Score, no significant correlation was found (p=0.54). Absolute differences in survival ≥20% were observed for the MRC Breathlessness Scale at 1, 2, and 3years, for the Charlson Comorbidity Index at 1year, and for the Age-Comorbidity Score at 2years. Thus, particularly the MRC Breathlessness Scale can contribute to personalization of the treatment of SCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
